SMO-话题@MedSci

#SMO#

285篇内容 | 2017人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=2024946, encodeId=005c202494690, content=<a href='/topic/show?id=c27516459de' target=_blank style='color:#2F92EE;'>#SMO#</a>, objectTitle=ESMO 2022：Nirogacestat改善了进展性硬纤维瘤患者的PFS（DeFi研究）, objectType=article, longId=739075, objectId=1b78e39075cc, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=1b78e39075cc, replyNumber=0, likeNumber=43, createdTime=2022-10-09, rootId=0, userName=liuhuangbo, userId=6779163, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=1b78e39075cc, moduleTitle=ESMO 2022：Nirogacestat改善了进展性硬纤维瘤患者的PFS（DeFi研究）, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=1b78e39075cc)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2024926, encodeId=d9f82024926bc, content=<a href='/topic/show?id=c27516459de' target=_blank style='color:#2F92EE;'>#SMO#</a>, objectTitle=ESMO Open：Nab-紫杉醇/吉西他滨和FOLFIRINOX作为一线序贯治疗转移性胰腺癌, objectType=article, longId=221332, objectId=bde422133214, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=bde422133214, replyNumber=0, likeNumber=31, createdTime=2021-12-22, rootId=0, userName=liuhuangbo, userId=6779163, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=bde422133214, moduleTitle=ESMO Open：Nab-紫杉醇/吉西他滨和FOLFIRINOX作为一线序贯治疗转移性胰腺癌, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=bde422133214)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2024951, encodeId=a3bd20249517c, content=<a href='/topic/show?id=c27516459de' target=_blank style='color:#2F92EE;'>#SMO#</a>, objectTitle=ESMO 2022：奥布替尼联合R-CHOP治疗既往未经治疗的non-GCB DLBCL患者的疗效和安全性, objectType=article, longId=739080, objectId=9bbfe3908038, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=9bbfe3908038, replyNumber=0, likeNumber=29, createdTime=2022-09-24, rootId=0, userName=liuhuangbo, userId=6779163, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=9bbfe3908038, moduleTitle=ESMO 2022：奥布替尼联合R-CHOP治疗既往未经治疗的non-GCB DLBCL患者的疗效和安全性, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=9bbfe3908038)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2024930, encodeId=ecde20249307d, content=<a href='/topic/show?id=c27516459de' target=_blank style='color:#2F92EE;'>#SMO#</a>, objectTitle=ESMO：帕博利珠单抗降低完全切除、早期非小细胞肺癌24%复发或死亡风险（KEYNOTE-091）, objectType=article, longId=301715, objectId=f4ef301e1547, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=f4ef301e1547, replyNumber=0, likeNumber=45, createdTime=2022-07-13, rootId=0, userName=liuhuangbo, userId=6779163, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=f4ef301e1547, moduleTitle=ESMO：帕博利珠单抗降低完全切除、早期非小细胞肺癌24%复发或死亡风险（KEYNOTE-091）, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=f4ef301e1547)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2024936, encodeId=250c20249368d, content=<a href='/topic/show?id=c27516459de' target=_blank style='color:#2F92EE;'>#SMO#</a>, objectTitle=【今晚直播】2022年ESMO指南摘要解读, objectType=article, longId=732437, objectId=e16de32437e6, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=e16de32437e6, replyNumber=0, likeNumber=15, createdTime=2022-11-20, rootId=0, userName=liuhuangbo, userId=6779163, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=e16de32437e6, moduleTitle=【今晚直播】2022年ESMO指南摘要解读, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=e16de32437e6)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2024937, encodeId=4e71202493e85, content=<a href='/topic/show?id=c27516459de' target=_blank style='color:#2F92EE;'>#SMO#</a>, objectTitle=2022年7月：ESMO发布ctDNA检测新建议！, objectType=article, longId=733658, objectId=88cbe33658e4, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=88cbe33658e4, replyNumber=0, likeNumber=35, createdTime=2023-01-15, rootId=0, userName=liuhuangbo, userId=6779163, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=88cbe33658e4, moduleTitle=2022年7月：ESMO发布ctDNA检测新建议！, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=88cbe33658e4)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2024917, encodeId=5dec202491e37, content=<a href='/topic/show?id=c27516459de' target=_blank style='color:#2F92EE;'>#SMO#</a>, objectTitle=ESMO Open：免疫检查点抑制剂相关的心血管不良事件的真实临床数据, objectType=article, longId=216690, objectId=9b99216690e2, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=9b99216690e2, replyNumber=0, likeNumber=32, createdTime=2022-06-23, rootId=0, userName=liuhuangbo, userId=6779163, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=9b99216690e2, moduleTitle=ESMO Open：免疫检查点抑制剂相关的心血管不良事件的真实临床数据, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=9b99216690e2)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2024933, encodeId=c87020249332c, content=<a href='/topic/show?id=c27516459de' target=_blank style='color:#2F92EE;'>#SMO#</a>, objectTitle=ESMO：化疗联合纳武利尤单抗对局部晚期可切除NSCLC治疗，42个月OS率达87.3%（NADIM研究）, objectType=article, longId=301725, objectId=d251301e254c, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=d251301e254c, replyNumber=0, likeNumber=28, createdTime=2023-03-11, rootId=0, userName=liuhuangbo, userId=6779163, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=d251301e254c, moduleTitle=ESMO：化疗联合纳武利尤单抗对局部晚期可切除NSCLC治疗，42个月OS率达87.3%（NADIM研究）, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=d251301e254c)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2024923, encodeId=491520249230f, content=<a href='/topic/show?id=c27516459de' target=_blank style='color:#2F92EE;'>#SMO#</a>, objectTitle=JAAD:短期口服vismodegib治疗高危或局部晚期基底细胞癌的各种组织学亚型的疗效、肿瘤反应率和安全性, objectType=article, longId=217734, objectId=763321e734eb, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=763321e734eb, replyNumber=0, likeNumber=53, createdTime=2022-03-21, rootId=0, userName=liuhuangbo, userId=6779163, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=763321e734eb, moduleTitle=JAAD:短期口服vismodegib治疗高危或局部晚期基底细胞癌的各种组织学亚型的疗效、肿瘤反应率和安全性, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=763321e734eb)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2024927, encodeId=f951202492e20, content=<a href='/topic/show?id=c27516459de' target=_blank style='color:#2F92EE;'>#SMO#</a>, objectTitle=陈洁：2021年ESMO年会我感兴趣的神经内分泌肿瘤相关摘要, objectType=article, longId=292477, objectId=9e8a2924e7c2, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=9e8a2924e7c2, replyNumber=0, likeNumber=31, createdTime=2022-03-11, rootId=0, userName=liuhuangbo, userId=6779163, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=9e8a2924e7c2, moduleTitle=陈洁：2021年ESMO年会我感兴趣的神经内分泌肿瘤相关摘要, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=9e8a2924e7c2)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2024925, encodeId=ce8f202492504, content=<a href='/topic/show?id=c27516459de' target=_blank style='color:#2F92EE;'>#SMO#</a>, objectTitle=ESMO Open：紫杉醇联合卡铂的一线方案加用贝伐珠单抗治疗复发性/转移性鼻咽癌, objectType=article, longId=221315, objectId=ce4a22131527, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=ce4a22131527, replyNumber=0, likeNumber=43, createdTime=2022-05-05, rootId=0, userName=liuhuangbo, userId=6779163, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=ce4a22131527, moduleTitle=ESMO Open：紫杉醇联合卡铂的一线方案加用贝伐珠单抗治疗复发性/转移性鼻咽癌, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=ce4a22131527)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2024924, encodeId=b6702024924c1, content=<a href='/topic/show?id=c27516459de' target=_blank style='color:#2F92EE;'>#SMO#</a>, objectTitle=ESMO Open：在抗肿瘤治疗的癌症患者中，BNT162b2冠状病毒2019信使RNA疫苗接种后体液免疫应答降低, objectType=article, longId=218280, objectId=a9bf2182807d, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=a9bf2182807d, replyNumber=0, likeNumber=31, createdTime=2021-12-02, rootId=0, userName=liuhuangbo, userId=6779163, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=a9bf2182807d, moduleTitle=ESMO Open：在抗肿瘤治疗的癌症患者中，BNT162b2冠状病毒2019信使RNA疫苗接种后体液免疫应答降低, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=a9bf2182807d)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2024922, encodeId=cf0c20249222f, content=<a href='/topic/show?id=c27516459de' target=_blank style='color:#2F92EE;'>#SMO#</a>, objectTitle=ESMO Open：奥斯替尼联合铂-培美曲塞用于EGFR突变的NSCLC患者的安全性和耐受性, objectType=article, longId=217452, objectId=1a0421e45297, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=1a0421e45297, replyNumber=0, likeNumber=42, createdTime=2021-11-14, rootId=0, userName=liuhuangbo, userId=6779163, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=1a0421e45297, moduleTitle=ESMO Open：奥斯替尼联合铂-培美曲塞用于EGFR突变的NSCLC患者的安全性和耐受性, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=1a0421e45297)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2024919, encodeId=26af20249191f, content=<a href='/topic/show?id=c27516459de' target=_blank style='color:#2F92EE;'>#SMO#</a>, objectTitle=ESMO Open：Tomuzotuximab vs 西妥昔单抗用作复发/转移性头颈部鳞癌的一线治疗方案的疗效和安全性, objectType=article, longId=217042, objectId=d10c21e042bc, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=d10c21e042bc, replyNumber=0, likeNumber=35, createdTime=2022-01-27, rootId=0, userName=liuhuangbo, userId=6779163, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=d10c21e042bc, moduleTitle=ESMO Open：Tomuzotuximab vs 西妥昔单抗用作复发/转移性头颈部鳞癌的一线治疗方案的疗效和安全性, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=d10c21e042bc)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2024928, encodeId=04a32024928c3, content=<a href='/topic/show?id=c27516459de' target=_blank style='color:#2F92EE;'>#SMO#</a>, objectTitle=ESMO OPEN：COVID-19背景下肿瘤学临床试验的新操作方法和地理差异, objectType=article, longId=293039, objectId=28fc2930390b, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=28fc2930390b, replyNumber=0, likeNumber=32, createdTime=2022-09-13, rootId=0, userName=liuhuangbo, userId=6779163, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=28fc2930390b, moduleTitle=ESMO OPEN：COVID-19背景下肿瘤学临床试验的新操作方法和地理差异, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=28fc2930390b)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2024910, encodeId=7048202491065, content=<a href='/topic/show?id=c27516459de' target=_blank style='color:#2F92EE;'>#SMO#</a>, objectTitle=ESMO Open：健康相关生活质量有助于预测卵巢癌患者的短期死亡风险！, objectType=article, longId=209635, objectId=20a620963560, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=20a620963560, replyNumber=0, likeNumber=0, createdTime=2022-01-09, rootId=0, userName=liuhuangbo, userId=6779163, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=20a620963560, moduleTitle=ESMO Open：健康相关生活质量有助于预测卵巢癌患者的短期死亡风险！, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=20a620963560)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2024912, encodeId=3e2220249120b, content=<a href='/topic/show?id=c27516459de' target=_blank style='color:#2F92EE;'>#SMO#</a>, objectTitle=ESMO Open：阿西替尼治疗肾细胞癌有害无益？, objectType=article, longId=210607, objectId=e78121060ee1, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=e78121060ee1, replyNumber=0, likeNumber=30, createdTime=2021-07-20, rootId=0, userName=liuhuangbo, userId=6779163, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=e78121060ee1, moduleTitle=ESMO Open：阿西替尼治疗肾细胞癌有害无益？, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=e78121060ee1)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2024929, encodeId=01b32024929b7, content=<a href='/topic/show?id=c27516459de' target=_blank style='color:#2F92EE;'>#SMO#</a>, objectTitle=罗氏 (Roche) 的双特异性Vabysmo获得FDA批准用于湿性AMD、糖尿病性黄斑水肿, objectType=article, longId=295101, objectId=9181295101bf, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=9181295101bf, replyNumber=0, likeNumber=36, createdTime=2022-12-31, rootId=0, userName=liuhuangbo, userId=6779163, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=9181295101bf, moduleTitle=罗氏 (Roche) 的双特异性Vabysmo获得FDA批准用于湿性AMD、糖尿病性黄斑水肿, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=9181295101bf)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2024921, encodeId=6967202492176, content=<a href='/topic/show?id=c27516459de' target=_blank style='color:#2F92EE;'>#SMO#</a>, objectTitle=ESMO 2021：嘉和生物杰诺单抗治疗中国复发/难治原发性纵隔大B细胞淋巴瘤的Ⅱ期临床研究结果公布, objectType=article, longId=217412, objectId=6fdf21e412ed, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=6fdf21e412ed, replyNumber=0, likeNumber=0, createdTime=2022-04-18, rootId=0, userName=liuhuangbo, userId=6779163, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=6fdf21e412ed, moduleTitle=ESMO 2021：嘉和生物杰诺单抗治疗中国复发/难治原发性纵隔大B细胞淋巴瘤的Ⅱ期临床研究结果公布, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=6fdf21e412ed)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2024911, encodeId=006e2024911d9, content=<a href='/topic/show?id=c27516459de' target=_blank style='color:#2F92EE;'>#SMO#</a>, objectTitle=Lancet Neurology：onasmonogene abeparvovec治疗有症状的婴儿型脊髓性肌萎缩症患者的3期临床试验, objectType=article, longId=209670, objectId=f8062096e0cf, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=f8062096e0cf, replyNumber=0, likeNumber=45, createdTime=2021-10-15, rootId=0, userName=liuhuangbo, userId=6779163, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=f8062096e0cf, moduleTitle=Lancet Neurology：onasmonogene abeparvovec治疗有症状的婴儿型脊髓性肌萎缩症患者的3期临床试验, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=f8062096e0cf)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 梅斯话题小助手

SMO

2020-05-29

liuhuangbo (审核中...)

前往app查看评论内容

#SMO#

ESMO 2022：Nirogacestat改善了进展性硬纤维瘤患者的PFS（DeFi研究）

2022-10-09

liuhuangbo (审核中...)

前往app查看评论内容

#SMO#

ESMO Open：Nab-紫杉醇/吉西他滨和FOLFIRINOX作为一线序贯治疗转移性胰腺癌

2021-12-22

liuhuangbo (审核中...)

前往app查看评论内容

#SMO#

ESMO 2022：奥布替尼联合R-CHOP治疗既往未经治疗的non-GCB DLBCL患者的疗效和安全性

2022-09-24

liuhuangbo (审核中...)

前往app查看评论内容

#SMO#

ESMO：帕博利珠单抗降低完全切除、早期非小细胞肺癌24%复发或死亡风险（KEYNOTE-091）

2022-07-13

liuhuangbo (审核中...)

前往app查看评论内容

#SMO#

【今晚直播】2022年ESMO指南摘要解读

2022-11-20

liuhuangbo (审核中...)

前往app查看评论内容

#SMO#

2022年7月：ESMO发布ctDNA检测新建议！

2023-01-15

liuhuangbo (审核中...)

前往app查看评论内容

#SMO#

ESMO Open：免疫检查点抑制剂相关的心血管不良事件的真实临床数据

2022-06-23

liuhuangbo (审核中...)

前往app查看评论内容

#SMO#

ESMO：化疗联合纳武利尤单抗对局部晚期可切除NSCLC治疗，42个月OS率达87.3%（NADIM研究）

2023-03-11

liuhuangbo (审核中...)

前往app查看评论内容

#SMO#

JAAD:短期口服vismodegib治疗高危或局部晚期基底细胞癌的各种组织学亚型的疗效、肿瘤反应率和安全性

2022-03-21

liuhuangbo (审核中...)

前往app查看评论内容

#SMO#

陈洁：2021年ESMO年会我感兴趣的神经内分泌肿瘤相关摘要

2022-03-11

liuhuangbo (审核中...)

前往app查看评论内容

#SMO#

ESMO Open：紫杉醇联合卡铂的一线方案加用贝伐珠单抗治疗复发性/转移性鼻咽癌

2022-05-05

liuhuangbo (审核中...)

前往app查看评论内容

#SMO#

ESMO Open：在抗肿瘤治疗的癌症患者中，BNT162b2冠状病毒2019信使RNA疫苗接种后体液免疫应答降低

2021-12-02

liuhuangbo (审核中...)

前往app查看评论内容

#SMO#

ESMO Open：奥斯替尼联合铂-培美曲塞用于EGFR突变的NSCLC患者的安全性和耐受性

2021-11-14

liuhuangbo (审核中...)

前往app查看评论内容

#SMO#

ESMO Open：Tomuzotuximab vs 西妥昔单抗用作复发/转移性头颈部鳞癌的一线治疗方案的疗效和安全性

2022-01-27

liuhuangbo (审核中...)

前往app查看评论内容

#SMO#

ESMO OPEN：COVID-19背景下肿瘤学临床试验的新操作方法和地理差异

2022-09-13

liuhuangbo (审核中...)

前往app查看评论内容

#SMO#

ESMO Open：健康相关生活质量有助于预测卵巢癌患者的短期死亡风险！

2022-01-09

liuhuangbo (审核中...)

前往app查看评论内容

#SMO#

ESMO Open：阿西替尼治疗肾细胞癌有害无益？

2021-07-20

liuhuangbo (审核中...)

前往app查看评论内容

#SMO#

罗氏 (Roche) 的双特异性Vabysmo获得FDA批准用于湿性AMD、糖尿病性黄斑水肿

2022-12-31

liuhuangbo (审核中...)

前往app查看评论内容

#SMO#

ESMO 2021：嘉和生物杰诺单抗治疗中国复发/难治原发性纵隔大B细胞淋巴瘤的Ⅱ期临床研究结果公布

2022-04-18

liuhuangbo (审核中...)

前往app查看评论内容

#SMO#

Lancet Neurology：onasmonogene abeparvovec治疗有症状的婴儿型脊髓性肌萎缩症患者的3期临床试验

2021-10-15

科室
- - 订阅+
  - 更多科室
工具
服务